glp 1 agonists in development Glucagon-like peptide-1 receptor: mechanisms and advances therapy π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Description
Physicians on Sermo share experiences with GLP-1 weight loss drugs and risks
Our licensed providers create custom treatment plans based on your unique goals and health history, with ongoing telehealth support every step of the way
In these cardiovascular safety trials, in secondary or exploratory analyses, GLP-1 receptor agonists were also shown to reduce macro-albuminuria, an accepted surrogate marker for diabetic kidney disease (DKD), a condition that still represents a major unmet medical need
Retatrutide, a new weight-loss drug, helped people lose 30% of their body weight in a study, rivaling results seen with weight-loss surgery.
Patients who suffer from the adverse effects of the weight loss injections may file for compensation
